Last reviewed · How we verify
TauroLock U 25000
TauroLock U 25000 is an antimicrobial lock solution that prevents biofilm formation and catheter-related bloodstream infections by combining taurolidine with heparin and uracil.
TauroLock U 25000 is an antimicrobial lock solution that prevents biofilm formation and catheter-related bloodstream infections by combining taurolidine with heparin and uracil. Used for Prevention of catheter-related bloodstream infections in patients with central venous catheters, Maintenance of central venous catheter patency.
At a glance
| Generic name | TauroLock U 25000 |
|---|---|
| Sponsor | Hamad Medical Corporation |
| Drug class | Antimicrobial lock solution |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Critical Care |
| Phase | FDA-approved |
Mechanism of action
The solution works by coating the internal lumen of central venous catheters with taurolidine, a broad-spectrum antimicrobial agent that disrupts bacterial and fungal biofilms. The addition of heparin prevents thrombosis, while uracil enhances antimicrobial efficacy. This lock therapy is instilled between uses to maintain catheter patency and reduce infection risk in patients requiring long-term central venous access.
Approved indications
- Prevention of catheter-related bloodstream infections in patients with central venous catheters
- Maintenance of central venous catheter patency
Common side effects
- Local catheter site reactions
- Thrombosis
- Infection despite prophylaxis
Key clinical trials
- Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |